Cargando…
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
The incidence of melanoma, among the most lethal cancers, is widespread and increasing. Metastatic melanoma has a poor prognosis, representing about 90% of skin cancer mortality. The increased knowledge of tumor biology and the greater understanding of the immune system role in the anti-tumor respon...
Autores principales: | Vanni, Irene, Tanda, Enrica Teresa, Spagnolo, Francesco, Andreotti, Virginia, Bruno, William, Ghiorzo, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338720/ https://www.ncbi.nlm.nih.gov/pubmed/32695793 http://dx.doi.org/10.3389/fmolb.2020.00113 |
Ejemplares similares
-
Current State of Target Treatment in BRAF Mutated Melanoma
por: Tanda, Enrica Teresa, et al.
Publicado: (2020) -
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020) -
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014) -
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma
por: Pastorino, Lorenza, et al.
Publicado: (2022) -
Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)